Immune monitoring of interleukin-7 compassionate use in a critically ill COVID-19 patient

Cell Mol Immunol. 2020 Sep;17(9):1001-1003. doi: 10.1038/s41423-020-0516-6. Epub 2020 Jul 29.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / diagnosis
  • Acute Kidney Injury / pathology
  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Antifungal Agents / therapeutic use
  • Betacoronavirus / immunology
  • Betacoronavirus / pathogenicity*
  • COVID-19
  • Compassionate Use Trials
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / genetics
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / virology
  • Critical Illness
  • Fatal Outcome
  • Humans
  • Immunologic Factors / therapeutic use*
  • Intensive Care Units
  • Interleukin-7 / therapeutic use*
  • Lymphopenia / drug therapy
  • Lymphopenia / genetics
  • Lymphopenia / immunology*
  • Lymphopenia / virology
  • Male
  • Pandemics
  • Pneumonia, Ventilator-Associated / diagnosis
  • Pneumonia, Ventilator-Associated / drug therapy
  • Pneumonia, Ventilator-Associated / etiology
  • Pneumonia, Ventilator-Associated / pathology
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / genetics
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / virology
  • Respiration, Artificial / adverse effects
  • SARS-CoV-2
  • Severe Acute Respiratory Syndrome / drug therapy
  • Severe Acute Respiratory Syndrome / genetics
  • Severe Acute Respiratory Syndrome / immunology*
  • Severe Acute Respiratory Syndrome / virology

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents
  • IL7 protein, human
  • Immunologic Factors
  • Interleukin-7